EPA:GNFTGenfit Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Genfit SA Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add €4.90 +0.14 (+2.94 %) (As of 06/5/2020 04:00 PM ET) Add Compare Share Today's Range€4.71Now: €4.90▼€5.0250-Day Range€4.76MA: €12.18▼€20.3052-Week Range N/AVolume1.07 million shsAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartCompetitorsHeadlines Genfit SA, a biopharmaceutical company, develops therapeutic and diagnostic solutions for metabolic, inflammatory, and autoimmune or fibrotic diseases affecting primarily the liver and gastro-enterology. The company's lead products include Elafibranor, which is in pivotal Phase 3 clinical trials for the treatment of nonalcoholic steatohepatitis (NASH), as well as in Phase 2 study in patients with primary biliary cholangitis; and Nitazoxanide that is in Phase 2 proof-of-concept clinical trial for the treatment of NASH-induced significant or severe fibrosis. It is also developing in-vitro diagnostic test for the identification of patients with NASH; and TGFTX1 preclinical program for treating psoriasis or respiratory conditions, such as neutrophilic asthma, chronic obstructive pulmonary disease (COPD), and the asthma-COPD overlap syndrome. Genfit SA was founded in 1999 and is headquartered in Loos, France.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Genfit. Previous Next 2.7 Community Rank Outperform VotesGenfit has received 13 “outperform” votes. (Add your “outperform” vote.)Underperform VotesGenfit has received 11 “underperform” votes. (Add your “underperform” vote.)Community SentimentGenfit has received 54.17% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Genfit and other stocks. Vote “Outperform” if you believe GNFT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe GNFT will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldGenfit does not currently pay a dividend.Dividend GrowthGenfit does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Genfit insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Previous Next Analyst Opinion: 0.0Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.54 out of 5 stars Industry, Sector and Symbol Stock Exchange EPA Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolEPA:GNFT Previous Symbol CUSIPN/A CIKN/A Webwww.genfit.com Phone33 3 20 16 40 00Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding SharesN/AMarket CapN/A Next Earnings DateN/A OptionableNot Optionable Receive GNFT News and Ratings via Email Sign-up to receive the latest news and ratings for GNFT and its competitors with MarketBeat's FREE daily newsletter. Genfit (EPA:GNFT) Frequently Asked Questions How has Genfit's stock been impacted by COVID-19 (Coronavirus)? Genfit's stock was trading at €12.78 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, GNFT stock has decreased by 61.6% and is now trading at €4.90. View which stocks have been most impacted by Coronavirus. Has Genfit been receiving favorable news coverage? Press coverage about GNFT stock has been trending very negative recently, according to InfoTrie. The research firm identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Genfit earned a news impact score of -3.0 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news aboutGenfit. Who are some of Genfit's key competitors? Some companies that are related to Genfit include Abattis Bioceuticals (ATTBF), ABcann Global (ABCN), ABZENA/PAR VTG FPD 0.002 (ABZA), Admedus (AHZ), AIkido Pharma (SONN), Almirall (LBTSF), Amarantus Bioscience (AMBS), Antibe Therapeutics (VBIZF), Apotheca Biosciences (CBDC), Arno Therapeutics (ARNI), Axim Biotechnologies (AXIM), Baudax Bio (BXRXV), BerGenBio ASA (BRRGF), Biocure Technology (CURE) and Canada House Wellness Group (CHV). View all competitors. What other stocks do shareholders of Genfit own? Based on aggregate information from My MarketBeat watchlists, some companies that other Genfit investors own include Pharming Group (PHGUF), NicOx (NICXF) and Genfit (GNFTF). Who are Genfit's key executives? Genfit's management team includes the following people: Mr. Jean-François Mouney, Co-Founder, CEO & Chairman (Age 64)Ms. Nathalie Huitorel, Exec. VP, Chief Financial & Admin. Officer (Age 58)Dr. Dean W. Hum, Chief Operating Officer (Age 57)Prof. Bart Staels, Co-Founder & Pres of the Scientific Advisory Board (Age 56)Mr. Laurent Lannoo, Corp. Sec. & Director of Legal Affairs (Age 49) What is Genfit's stock symbol? Genfit trades on the EPA under the ticker symbol "GNFT." What is Genfit's stock price today? One share of GNFT stock can currently be purchased for approximately €4.90. What is Genfit's official website? The official website for Genfit is www.genfit.com. How can I contact Genfit? The company can be reached via phone at 33 3 20 16 40 00. This page was last updated on 6/5/2020 by MarketBeat.com Staff
